Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002997753 | SCV003709956 | uncertain significance | Inborn genetic diseases | 2021-09-17 | criteria provided, single submitter | clinical testing | The c.3712G>A (p.D1238N) alteration is located in exon 4 (coding exon 3) of the SETBP1 gene. This alteration results from a G to A substitution at nucleotide position 3712, causing the aspartic acid (D) at amino acid position 1238 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003548937 | SCV004266460 | benign | not provided | 2024-05-14 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004736296 | SCV005352830 | uncertain significance | SETBP1-related disorder | 2024-07-28 | no assertion criteria provided | clinical testing | The SETBP1 c.3712G>A variant is predicted to result in the amino acid substitution p.Asp1238Asn. This variant was reported in an individual with neurodevelopmental disorder (Supplementary Data 5, Wang et al 2020. PubMed ID: 33004838). This variant is reported in 0.012% of alleles in individuals of African descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |